These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26885437)

  • 41. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
    Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
    Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Side effects of high-dose intravenous immunoglobulins.
    Stangel M; Hartung HP; Marx P; Gold R
    Clin Neuropharmacol; 1997 Oct; 20(5):385-93. PubMed ID: 9331514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-Gal IgM, IgA and IgG natural antibodies in childhood.
    Hamanova M; Chmelikova M; Nentwich I; Thon V; Lokaj J
    Immunol Lett; 2015 Mar; 164(1):40-3. PubMed ID: 25684746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous immunoglobulins: clinical experience and viral safety.
    Ballow M
    J Am Pharm Assoc (Wash); 2002; 42(3):449-58; quiz 458-9. PubMed ID: 12030632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Developing therapeutic immunoglobulins: European regulatory perspectives and implications.
    Kurz M
    BioDrugs; 2008; 22(3):145-60. PubMed ID: 18481898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins.
    Werdan K
    Ther Apher; 2001 Apr; 5(2):115-22. PubMed ID: 11354295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of infliximab in dermatology.
    Rott S; Mrowietz U
    J Dtsch Dermatol Ges; 2007 Aug; 5(8):655-60. PubMed ID: 17659038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Indications for intravenous immunoglobulins].
    Mouthon L
    Presse Med; 2006 Apr; 35(4 Pt 2):714-9. PubMed ID: 16614620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The use of human immunoglobulins--adverse reactions].
    Pituch-Noworolska A; Błaut-Szlósarczyk A; Zwonarz K
    Pol Merkur Lekarski; 2010 Sep; 29(171):202-5. PubMed ID: 20931833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.
    Schwab I; Seeling M; Biburger M; Aschermann S; Nitschke L; Nimmerjahn F
    Eur J Immunol; 2012 Dec; 42(12):3302-9. PubMed ID: 22945870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?
    Aries PM; Hellmich B; Gross WL
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):237-45. PubMed ID: 16391399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases.
    Imazio M; Lazaros G; Picardi E; Vasileiou P; Carraro M; Tousoulis D; Belli R; Gaita F
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):263-9. PubMed ID: 26090917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum IgG subclass concentrations before and after administration of intravenous immunoglobulin in common variable immunodeficiency.
    Ozawa T; Motoyoshi F; Kato Y; Kondo N; Orii T
    J Clin Lab Immunol; 1992; 38(1):29-39. PubMed ID: 1343346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Old and current aspects of intravenous immunoglobulin therapy].
    Nydegger U
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):5-25. PubMed ID: 8296191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction.
    Fuchs S; Feferman T; Zhu KY; Meidler R; Margalit R; Wang N; Laub O; Souroujon MC
    Ann N Y Acad Sci; 2007 Sep; 1110():550-8. PubMed ID: 17911471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimation of serum and tissue immunoglobulins level in some colonic disorders.
    Fahmy OA; Abdel-Fattah SA; Fahmy IA; Mokhtar I; el-Maragy MM
    J Egypt Soc Parasitol; 1991 Aug; 21(2):503-12. PubMed ID: 1908501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low-avidity IgG against Epstein-Barr virus capsid antigen in children.
    Votava M; Bartosová D; Krchnáková A; Crhová K; Kubinová L
    Acta Virol; 1996 Apr; 40(2):99-101. PubMed ID: 8886119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Mechanisms of action of intravenous immunoglobulins].
    Poehlau D; Postert T; Rieks M; Baier J; Nastos I; Amoiridis G; Schimrigk S; Hoffmann V; Przuntek H
    Fortschr Med; 1996 Nov; 114(31):420-4. PubMed ID: 9036095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia.
    Stahl D; Sibrowski W
    Curr Pharm Des; 2003; 9(23):1871-80. PubMed ID: 12871191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of high-dose immunoglobulins in dermatology.
    Enk A; Fierlbeck G; French L; Hertl M; Messer G; Meurer M; Steinbrink K; Stingl G; Volc-Platzer B; Zillikens D
    J Dtsch Dermatol Ges; 2009 Sep; 7(9):806-812. PubMed ID: 19624804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.